Nanomedicine platforms targeting senescent cells—including lipid-based, polymeric, hybrid, and biomimetic systems—demonstrate theoretical advantages over free senolytic drugs through controlled exposure and multi-step cellular selectivity, yet lack definitive clinical efficacy validation. The analysis highlights critical limitations: senescent cell heterogeneity complicates universal targeting, nanoparticle accumulation remains uncertain in poorly perfused aged tissues, and most studies focus on encapsulation efficiency rather than functional recovery outcomes. This assessment arrives at a pivotal moment in aging research. With senolytics like dasatinib-quercetin showing mixed clinical results and companies like Unity Biotechnology scaling back senotherapy programs, the field requires more sophisticated delivery strategies. Nanomedicine could theoretically solve key senolytic challenges—narrow therapeutic windows, off-target toxicity, and inconsistent tissue penetration—but the gap between preclinical promise and clinical translation remains substantial. The emphasis on 'biology-to-design integration' reflects growing recognition that successful senotherapy requires understanding senescent cell biology first, then engineering delivery systems accordingly. This represents a maturing field moving beyond proof-of-concept toward clinically viable interventions, though meaningful human validation remains the critical next step.